Revenue $16.61B, up 5.1% on a year earlier. Animal Health Sales $1.77B, up 7.8%. Pharmaceutical Sales $14.76B, up 5.1%. Diluted EPS -$0.54 against $1.76.
| Q2 FY26 | Q1 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|---|
| Revenue | $16.61B | $16.29B | $15.81B | +5.1% |
| Net income | -$1.33B | -$4.24B | $4.43B | -130.1% |
| Diluted EPS | -$0.54 | -$1.72 | $1.76 | |
| Operating cash flow | $5.37B | $3.92B | $3.29B | +63.1% |
| Capital expenditures | -$893.00M | -$991.00M | -$764.00M | |
| Free cash flow | $4.48B | $2.93B | $2.53B | +77.0% |
| Dividend per share | $0.85 | $0.85 | $0.81 |
| Q2 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|
| Animal Health Sales | $1.77B | $1.65B | +7.8% |
| Pharmaceutical Sales | $14.76B | $14.05B | +5.1% |
| Gardasil Sales | $1.17B | $1.13B | +3.8% |
| Januvia / JANUMET Sales | $429.00M | $372.00M | +15.3% |
| BRIDION Sales | $497.00M | $461.00M | +7.8% |
| Keytruda Sales | $7.90B | $7.96B | -0.7% |
| Lynparza Alliance Revenue | $365.00M | $370.00M | -1.4% |
| Lenvima Alliance Revenue | $283.00M | $265.00M | +6.8% |
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “Merck (MRK) Q2 FY26 earnings: results and KPIs”, stockatlas.com/companies/MRK/earnings/2026-q2/, data as of 3 November 2026. Links to this page are welcome.
